RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO Annual Meeting ...Middle East

PR Newswire - News
RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO Annual Meeting
YANTAI, China, May 23, 2022 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK, SHA: 688331), a commercial-stage biotechnology company, today announced that three abstracts for disitamab vedotin (RC48) have been selected for poster discussions by the 2022 American Society of Clinical Oncology...

Hence then, the article about remegen to present three studies on disitamab vedotin at 2022 asco annual meeting was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO Annual Meeting )

Apple Storegoogle play

Last updated :

Also on site :